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ABSTRACT 
Herbarin A and B were isolated from the fungal strains of Cladosporium herbarum found 
in marine sponges Aplysina aerophoba and Callyspongia aerizusa. Total synthesis of Herbarin A 
and B was achieved by carrying out a multi-step synthesis approach, and the antioxidant properties 
were evaluated using FRAP assay. Toxicity of these compounds was determined using a zebrafish 
embryo model.  Furthermore, synthesis of C-6 alkyl-azaarene derivatives of nucleosides by Csp3-
H bond functionalization were investigated. Effective incorporation of 2-methylazaarene moiety 
at the C-6 position of the protected inosine nucleoside provided a new class of compounds with 
anticipated enhanced biological activity.   
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CHAPTER 1 
INTRODUCTION 
1.1 NATURAL PRODUCT SYNTHESIS 
The first syntheses of Herbarin A and B have been successfully achieved.1 Herbarin A and 
B, two new α-pyrone derivatives,were isolated from fungal strains in marine sponge.2 These 
compounds were found to exhibit potent toxicity as secondary metabolites of aquatic 
microorganisms, a rich source of biologically active compounds.3  
Extensive research continues to test biological activity of structurally unique secondary 
metabolites from marine sponge as potential natural synthesis products. Studies suggest that there 
can be a significant increase in the harvest of these potential biologically active metabolites. The 
marine sponge derivatives, due to the increased degree of biodiversity, demonstrate promise in 
experimental and clinical models.3 The sponge-associated fungal metabolites Herbarin A and B, 
isolated from marine sponges Aplysina aerophoba and Callyspongia aerizusa, have been found to 
exhibit inhibitory biological activity against strains of the fungus Cladosporium herbarum.2 
Potential applications of Herbarin A and B include uses as antitumor agents, herbicides, and 
antimicrobials.3 As a consequence of their remarkable activity and unique chemical structure, a 
multi-step synthetic route to afford Herbarin A and B in multi-gram scale quantities, a feat not 
possible from their natural source, was successfully achieved. 3  
Development of a synthetic strategy to permit preparation of multi-gram quantities of the 
target compounds as well as structural derivatives is useful for exploring structure-activity 
relationships and compounds’ mode of action.2 The current research demonstrates that Herbarin A 
and B exhibit antioxidant properties and toxicity in zebrafish embryo models. The amount of 
compound required for these experiments are relatively large (0.1-1.0 g and more) and are difficult 
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to obtain from the natural source. Furthermore, the process of isolating pure Herbarins from their 
natural source is very labor-intensive and time consuming. As such, the chemical syntheses of 
gram scale quantities of the compounds from commercially available starting material proved 
highly useful. 
 
1.2 SYNTHESIS OF NUCLEOSIDE DERIVATIVES  
Nucleosides, although not toxic alone, have been and continue to be researched as their 
presence in living systems make excellent scaffolds for chemical modification. Modified 
nucleoside derivatives can play an important biological role, for example as modulators of 
adenosine receptors, stimulators of plant cell growth and cell division, inhibitors of DNA 
polymerases towards normal and cancer cells, and as antiviral compounds.4-9 Recently, a class of 
C-6 aryl purine ribonucleosides has been shown to possess cytostatic activity toward T-
lymphoblastoid and other cell lines.11 Owing to the interesting biological properties of modified 
nucleosides, a number of synthetic protocols have been developed to effectively functionalize the 
C-6 position. Some of these protocol include palladium-catalyzed C-C bond formation and Suzuki 
cross coupling reactions.12-14 These known methods have led to the development of several 
nucleoside analogues. 19  
 The structural core of quinoline is frequently associated with medicinal applications, such 
as anti-cancer, antimicrobial, HIV-1 integrase inhibitors, HIV protease inhibitors, anti-leishmanial 
activity, and NK-3 receptor antagonists.15,16 Owing to their wide applications, the synthesis of 
quinoline and its derivatives have attracted considerable attention of organic and medicinal 
chemists for many years.17,18  In the proposed work, synthetic approaches combine two biologically 
active cores, nucleosides and quinoline, to produce a new class of compounds with a synergistic 
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effect that will enhance biological activity. Utilization of a recently developed, novel Csp3-H 
functionalization strategy to effectively incorporate alkyl-azaarene moiety at the C-6 position of 
nucleosides is discussed.10 Notably, functionalization of nucleosides with azaarenes has not yet 
been reported in the literature.4-9    
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CHAPTER 2 
TOTAL SYNTHESIS OF HERBARIN A AND B, DETERMINATION OF THEIR 
ANTIOXIDANT PROPERTIES, AND TOXICITY IN ZEBRA FISH EMBRYO MODEL   
 
2.1 INTRODUCTION 
Herbarin A and B, were recently isolated by Jadulco and co-workers 2 from two strains of 
the fungi Cladosporium herbarum found in sponges Aplysina aerophoba and Callyspongia 
aerizusa respectively. Spectroscopic analysis of ethyl acetate extracts from these fungi revealed 
two new -pyrone derived structures, Herbarin A and B. Various spectroscopic techniques such 
as, NMR and mass-spectrometry were used for structural elucidation. To determine the initial 
biological activity, a feeding assay was performed on polyphagous pest insect larvae and brine 
shrimp larvae.2, 3 
As a consequence of their potent toxicity towards insect and brine shrimp larvae and unique 
chemical structure, laboratory syntheses of Herbarin A and B (Figure 1) was pursued.  A multistep 
synthetic approach provided the target compounds in multi-gram scale quantity, which is not 
possible from the natural source. Having the larger quantities allowed for further investigation of 
the potential toxicity and antioxidant properties of these natural products. 
 
 
 
 
 
Figure 1. Structures of Herbarin A and Herbarin B 
 
5 
 
2.2 RESULTS AND DISCUSSION  
Herein, synthesis of target compounds using a multi-step reaction sequence has been 
described, as demonstrated below (Scheme 1). Aldehyde (7), was identified as the crucial 
intermediate that can afford both the target compounds.  
 
Scheme 1. Synthetic strategy for Herbarin B 
 
As a first step, research efforts were directed towards the synthesis of 4-hydroxypyrone (5) 
by utilizing commercially available starting materials as basic building blocks and using a 
modified approach described by Wilcox and group.20 3-Methyl-2,4-pentanedione (3) was treated 
with NaNH2 and then reacted with dry ice to provide diketo-acid (4) in 77% crude yield. A simple 
acid base reaction (Scheme 2) first picks up a proton, providing a dianion mechanism, thus 
addition of excess base is required. Addition of the nucleophile, followed by treatment with acid 
provided crude diketo-acid.  
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Scheme 2. Dianion Carbonyl Mechanism  
 
Diketo-acid (4) without any purification was then treated with HF (Scheme 2) to afford the 
4-hydroxypyrone (5) in about 39% yield. The cyclization mechanism is provided below (Scheme 
3). Upon further treatment with acid, protonation of crude diketo-acid followed by nucleophilic 
addition of the 2-carbonyl to C-6, closes the ring providing the pyrone core. The closed ring then 
picks up a proton from acid. The strong nucleophile, Fluorine, picks up a proton resulting in an 
elimination reaction, providing a double bond between C-5 and C-6. This dehydration reaction 
provides keto-enol tautomerization products, in which the enol product is favored as it is aromatic, 
and thus more stable.  
 
Scheme 3. Cyclization Mechanism 
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Additionally, etherification provided 4-methoxypyrone (6) as a yellow solid in 81% 
isolated yield, and upon oxidation with SeO2 selectively converted the methyl group at position C-
6 to aldehyde (7) in quantitative yield. 4-methoxypyrone (6) starting material and product (7) were 
inseparable when subjected to flash chromatography, thus a crude mixture of (7) was obtained as 
a yellow solid in 88% yield. After successful execution of the synthetic scheme, aldehyde (7) was 
synthesized in multi-gram quantities to be utilized in further reactions.      
Aldehyde (7) was then reacted with phosphonate ester (8) using Horner–Wadsworth–
Emmons coupling strategy to obtain an exclusively trans-alkene (9) in about 90% yield.21 
Hydrolysis of the ester group with 3M HCl yielded Herbarin B (2) as a white solid in 98% yield. 
All products were purified using column chromatography and structure elucidation was carried 
out using various spectroscopic techniques including NMR and mass-spectrometry. Lastly, the 
spectroscopic data for Herbarin B was compared with literature data to confirm the product 
formation. Herbarin B was deliberately chosen as the first synthetic target considering its lesser 
complexity compared to Herbarin A. 
 After successfully accomplishing the synthesis of Herbarin B, Herbarin A was targeted by 
using a similar synthetic scheme. The aldehyde intermediate (7) was treated with commercially 
available predominantly trans-phosphonate ester (10) to form an exclusively trans-trans-ester (11) 
in 81% yield, which on further hydrolysis with 3M HCl provided Herbarin A in 67% yield 
(Scheme 4).    
 
 
Scheme 4. Synthetic strategy for Herbarin A 
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2.3 DETERMINATION OF ANTIOXIDANT PROPERTIES 
 
Ferric Reducing Ability of Plasma (FRAP) Assay:  A wide range of assays is known for 
measuring the reducing capacity of antioxidants. The assays are carried out at acidic (FRAP), 
neutral (TEAC), or basic (total phenols assay FCR) conditions. The pH values have an important 
effect on the reducing capacity of antioxidants.22 Herbarin A and B both have carboxylic acid 
groups and to maintain the integrity of these molecules, we choose to use the acidic FRAP assay. 
Also FRAP assay has several advantages such as high reproducibility, simple, rapidly performed 
and showed the highest efficiency for acids and phenols.23 Therefore, it would be an appropriate 
technique for determining antioxidant activity for Herbarin A and B.  
The FRAP assay, is presented as a novel method for assessing ‘‘antioxidant power.’’ Ferric 
to ferrous ion reduction at low pH causes a colored ferrous-tripyridyltriazine complex to form. 
FRAP values are obtained by comparing the absorbance change at 593 nm in test reaction mixtures 
with those containing ferrous ions in known concentration. Absorbance changes are linear over a 
wide concentration range with antioxidant mixtures, including plasma, and with solutions 
containing one antioxidant in purified form.24 The FRAP assay is inexpensive, reagents are simple 
to prepare, results are highly reproducible, and the procedure is straightforward and speedy. The 
FRAP assay offers a putative index of antioxidant, or reducing potential of organic compounds 
within the technological reach of every laboratory.  
The FRAP assay was employed as described in the literature.25 The mechanism of this 
method is based on the reduction of ferric 2,4,6-tripyridyl-s-triazine complex (Fe3+-TPTZ) to its 
ferrous form (Fe2+-TPTZ) in the presence of antioxidants (Figure 2).  
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Figure 2. Reduction of Fe3+-TPTZ to Fe2+-TPTZ: Cuvette A contained FRAP reagent 
and dH2O as a blank, and cuvettes B-F contained a series of dilutions with Herbarin B at 10, 20, 
40, and 80 μg/mL respectively.  
 
FRAP reagent solution was prepared by addition of 25 mL acetate buffer, 2.5 mL of Fe3+-
tripyridyl-triazine (Fe3+-TPTZ) (10 mmol/L in 40 mmol/L of HCl, and 2.5 mL FeCl3 (20 mmol/L). 
Herbarin A was then added to (300 μL) of the FRAP reagent solution (at 10, 20, 40, and 80 μg/mL), 
followed by 30 μL distilled H2O and absorbance of the samples were recorded at 593 nm. Herbarin 
B followed the same procedure and dilution series as Herbarin A, exactly (Figure 2).  
The electron-donating capacity of the antioxidant was measured by the change in 
absorbance at 593 nm; the blue-colored Fe2+-tripyridyl-s-triazine (Fe2+-TPTZ) compound was 
formed from the initial colorless solution (Fe3+-TPTZ). The absorbance of the reaction mixture 
was measured spectrophotometrically at 593nm after incubation at room temperature for 1 hour. 
Calibration curves were generated from aqueous solutions of FeSO4 at different concentrations 
A B C D E F 
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ranging from 0.1 to 1 mM. A series of dilution standards were prepared from a fresh 1mM solution 
of FeSO4.7H2O in dH2O to construct a linear regression (absorbance against concentration) and 
compare FRAP  values (units, mM Fe(II) per litre) of the samples to the known Fe(II) 
concentration of the calibration standard. Both Herbarin A and B showed activity towards 
antioxidant assay at 0.1 to 1 mM concentrations (Figure 3). 
 
 
 
Figure 3. Antioxidant activity of Herbarin A and B 
 
2.4 TOXICITY ASSAY 
To assess the biological value of Herbarin A and B, we used a zebrafish embryo screening 
assay. Herbarin A and B were tested for toxicity and teratogenicity in zebrafish embryos.26-30 These 
assays were performed using an established literature procedure.26-30 Briefly, wild-type zebrafish 
embryos were collected from spawn tanks and allowed to grow until 6 hpf (hours post fertilization) 
at standard conditions.31  At 6 hpf, embryos were observed under a microscope for embryonic 
development and only normally developing embryos were transferred to wells in 24-well plate and 
allowed to grow in 1 mL of treatment solution for up to 2 dpf (days post fertilization). Observations 
0
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were made at 24 hpf and solutions were replaced as necessary. Herbarin A and B were dissolved 
in 100% DMSO after purification, further they were re-suspended in E3 (embryonic medium) at 
various concentrations (Figure 4 and 5) for zebrafish assay. Therefore our controls were WT 
(wild-type) embryos in E3 with same concentrations of DMSO (Figure 5, A and B) as in Herbarin 
A and B solutions. This study had identified that Herbarin B is more biologically active than 
Herbarin A (Figure 4 and 5).  
Lethality assay was performed at concentrations from 9 nM to 475 nM and these studies 
revealed that Herbarin B has an LD50 (50% lethal dose) of 190 nM (Figure 4). Herbarin B 
displayed dynamically increasing lethality from 9 nM to 190 nM concentrations beyond which it 
is completely lethal (Figure 4). Herbarin B was also 100% teratogenic at concentrations of 9 nM 
to 190 nM (Figure 5). Teratogenic phenotypes were specific showing a shortened body axis 
resembling gastrulation defects during early development, dorsal curvature of the trunk, tail 
malformations and pericardial edema (Figure 5, E and F; black arrows denote dorsal curvature of 
trunk and tail malformations). While Herbarin B was lethal and teratogenic, Herbarin A appeared 
to be a docile compound with no observed toxicity and teratogenicity at similar concentrations 
(Figure 5, C and D). The zebrafish assay was performed in triplicate. Statistical analyses using 
student t-test revealed significant difference (Figure 3; *p<0.001) between DMSO control and 
Herbarin B observations and no significant differences (Figure 3; **p<0.001) between DMSO 
control and Herbarin A treatment. In summary, the zebrafish assays have identified that Herbarin 
B is more biologically active compared to Herbarin A. 
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Figure 4: Quantitative summary of lethality and teratogenicity in zebrafish embryos 
 
 
 
 
 
Figure 5: Zebrafish Development in Herbarin A and Herbarin B Treatment. 
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CHAPTER 3 
FUNCTIONALIZATION OF NUCLEOSIDES WITH 2-METHYL AZAARENES AT 
C-6 POSITION  
 
3.1 INTRODUCTION 
Recent investigations carried out in our laboratory proved the vital role of a Lewis acid 
Yb(OTf)3 as a catalyst in Csp
3-H bond functionalization of methyl azaarenes with α-
trifluoromethylated carbonyl compounds.9 We utilized novel Csp3-H bond functionalization of 2-
methyl azaarenes with ethyl trifluoropyruvate and found the addition of 5 mol% of Yb(OTf)3 
catalyst (under optimized conditions) provided quantitative product yields. This methodology has 
been successfully extended for the functionalization of nucleosides with various azaarenes. 
Various reaction conditions including Lewis/Brønsted acids and bases were utilized to determine 
optimal reaction conditions for this synthesis. 
 
3.2 RESULTS 
Strategy 1: Inosine (12) was chosen as the nucleoside and quinaldine (15) as its azaarene 
counterpart. For the first step, inosine was reacted with TBDMS-Cl to fully protect all hydroxyl 
groups on the ribose (13). Treatment with SOCl2 provided conversion of the hydroxyl group at C-
6 position to –Cl, creating a better leaving group. The halogenated nucleoside product (14) was 
then subjected to Csp3-H functionalization with quinaldine (15) in presence of various catalyst and 
reaction conditions for the displacement of chloride from the C-6 position as described below 
(Scheme 5).  
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Scheme 5. Proposed synthetic plan for C-6 alkyl-quinoline nucleosides using C-6 chloro-inosine 
derivative 
 
 Conversion of the hydroxyl group at the C-6 position of the protected inosine product (13) 
was investigated. Optimization trials were then conducted by treatment with SOCl2 under various 
solvent and reaction conditions. Protected inosine (100 mg, 0.1637 mmol) was dissolved in 10 mL 
dry DCM under argon, followed by the addition of DMF (0.5 mL). Reaction temperature was then 
reduced to 0°C in an ice bath, followed by the addition of SOCl2 (1.2 equiv, 14.25 µL, 0.19646 
mmol). The reaction mixture was then warmed to room temperature and allowed to proceed for 2 
h. Solvent was then evaporated and the concentrated product was used as starting material for 
reaction optimization trials, targeting product (16) as depicted above (Scheme 5). Trial reactions 
with DBU under various temperature conditions of 80°C and 110°C for 12 h did not provide the 
expected product. Trials with NEt3 (2 Equiv, 45.63 µL, 0.32744 mmol) were utilized instead of 
DBU. All other reaction conditions were carried out as described above.  
Trials utilizing quinaldine (15) in presence of various catalyst and reaction conditions to 
facilitate displacement chloride from the C-6 position as described above (Scheme 5) did not 
provide satisfactory results. Further the role of various Lewis acid and Brønsted acid catalysts was 
15 
 
evaluated. Optimization reactions under various solvents, and temperature conditions are 
described in Table 1.   
Table 1. Optimization of Various Lewis acid and Brønsted acid catalysts 
 
Entry Catalyst Solvent Temp (°C) % Yield 
of (16) 
1 Yb(OTf)3. Dioxane 80 0 
2 Yb(OTf)3. Dioxane 100 0 
3 Yb(OTf)3. Dioxane 110 0 
4 
 
Dioxane 80 0 
5 
 
Toluene 115 0 
6  Dioxane 80 0 
7  Toluene 115 0 
8  Dioxane 80 0 
9  Dioxane 80 0 
 
 
Strategy 2: C-6 hydroxy group was converted to mesitylenesulfonate (19) as described in 
the literature.18 Further treatment with diazabicycloundecene (DBU) and triethylamine followed 
by addition of quinaldine (15) provided the expected TBDMS protected conjugated product (16) 
16 
 
under one pot conditions. Addition of a quinaldine nucleophile under SNAr displacement 
mechanism of the mesitylenesulfonate provided C-6 substituted nucleoside. Deprotection with 
TBAF (Tetrabutylammonium fluoride) provided the 2-methyl azaarene-inosine conjugated 
product (17). 
 
Scheme 6. Proposed synthetic plan for C-6 alkyl-quinoline nucleosides using C-6 
mesitylenesulfonate inosine derivative 
 
The above described reaction strategy was then utilized for the Csp3-H bond 
functionalization of 2-methyl pyridine (20) with C-6 position of inosine (Scheme 7). The reaction 
worked as expected and the resulting conjugated product (21) was obtained in good yields. Further 
deprotection with TBAF provided the 2-methyl pyridine-inosine conjugated product (22). 
17 
 
Scheme 7. Proposed synthetic plan for C-6 alkyl-pyridine nucleosides 
 
Conversion of the C-6 hydroxyl group was successfully achieved utilizing the bulky 
leaving group (18) will be subjected to the optimized reaction conditions with various substituted 
azaarenes. The methodology will also be utilized to functionalize other various nucleosides such 
as guanosine and 5-methyluridine to get a diverse group of compounds. All the products will be 
subjected to toxicity assay and also, their anti-viral properties will be determined. External 
collaboration will be sought in order to determine the anti-viral properties of the products 
synthesized. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
In conclusion, the synthesis of Herbarin A and Herbarin B has been successfully achieved 
utilizing commercially available starting materials and following known literature synthetic 
protocols. All the products were characterized by use of analytical techniques. The antioxidant 
activity of target compounds was investigated. Furthermore, the toxicity assay using zebrafish 
embryo was also investigated. Herbarin B was found to exhibit toxicity and be lethal as determined 
by zebrafish embryo model.  
Csp3-H bond functionalization of 2-methyl azaarenes to protected inosine were found 
successful utilizing a bulky leaving group at the C-6 position of protected inosine. Future directions 
include optimization of reaction conditions to afford nucleoside derivatives. Additionally, various 
2-methyl azaarenes will be functionalized at the C-6 position as described in the present work. To 
evaluate the generality of the above method, mesitylenesufonate will be subjected to the optimized 
reaction conditions with various substituted azaarenes. The methodology will also be utilized to 
functionalize various other nucleosides such as guanosine and 5-methyluridine to get a diverse 
group of compounds. All products will be subjected to toxicity assay and anti-viral properties will 
be determined. 
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APPENDIX A 
ANALTICAL METHODS 
 
MATERIALS: All the starting materials were purchased from Aldrich and used without further 
purification. Anhydrous solvents were obtained as follows: anhydrous tetrahydrofuran was distilled from 
sodium metal under argon, anhydrous dichloromethane was dried via distillation from CaH2 immediately 
prior to use under argon, and anhydrous toluene was stored at 4 Å molecular sieves before use. Other 
solvents used in synthesis with minimum purity of 99.5% were Aldrich products. CDCl3 and CD3OD 
were used as solvents (99.8%) for the NMR studies. Thin Layer Silica Gel Chromatography Plates (60 
Å, 250 µm thickness, F-254 indicator). Flash chromatography was performed using 230-400 mesh, 60 
Å pore diameter silica gel. Chromatography solvents used were reagent grade.  
 
NMR ANALYSIS: The 1H NMR spectra were obtained at 400 MHz using Agilent NMR spectrometer. 
13C NMR spectra were recorded at 100 MHz. Chemical shifts are reported in parts per million and are 
referenced to the deuterated residual solvent peak. NMR data is reported as: δ value (chemical shift, J-
value (Hz), integration, where s = singlet, d = doublet, t = triplet, q = quartet, bs = broad singlet).  
 
All the melting points are uncorrected and recorded on MEL-TEMP. 
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APPENDIX A 
SUPPORTING INFORMATION CHAPTER 2 
 
Synthesis of 4-hydroxy-5, 6-dimethyl-2-pyrone (5) 
 
 
 
Compound (5) was synthesized using a modified approach as describe by Wilcox (J. Am. Chem. Soc. 
1988, 110, 470-481). 3-Methyl-2,4-pentanedione (4.9 g, 42.9 mmol) was reacted with freshly prepared 
NaNH2 and dry ice to obtain a diketoacid (4). Further treatment of (4) with HF provided the hydroxy 
pyrone (5) (2.33 g, 39 %) as red crystals. mp 209.2-210.5 oC.1H NMR (400 MHz, CD3OD), δ (ppm) 
5.39 (s, 1H), 2.23 (s, 3H), 1.91 (s, 3H).13C NMR (100.53 MHz, CD3OD), δ (ppm) 173.4, 168.2, 160.6, 
109.4, 89.6, 17.51, 9.56, MS-C7H8O3 (140.05), m/z (%): Found 140 (M
+) 
  
Synthesis of 4-methoxy-5,6-dimethyl-2-pyrone (6) 
  
Hydroxy pyrone (660 mg, 4.7 mmol) and dimethyl sulfate (500 µL, 5.18 mmol) were placed in round 
bottom flaks along with 10 mL of acetone. Potassium carbonate (4 g, 6 eqv.) was the added and the 
reaction mixture was refluxed for 15 h under argon. The reaction mixture was filtered through sintered 
glass funnel; resulting filtrate was concentrated and then subjected to flash chromatography. Product 
eluted with 1:1 mixture of hexanes and ethyl acetate to get a yellow solid (586 mg, 81%) isolated yield. 
Yellow solid, mp 101.7-103.0 oC, 1H NMR (400 MHz, CDCl3), δ (ppm) 5.38 (s, 1H), 3.76 (s,3H), 2.15 
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(s, 3H), 1.81 (s, 3H). 13C NMR (100.53 MHz, CDCl3), δ (ppm) 170.9, 164.6, 157.6, 106.8, 87.8, 56.0, 
17.2, 9.4, MS-C8H10O3 (154.06), m/z (%): Found 154 (M
+)  
 
Synthesis of 6-carboxaldehyde-4-methoxy-5-methyl-pyr-2-one (7) 
 
 
Methoxypyrone (6) (535 mg) was placed in a round-bottom flask along with 10 mL 1,4-dioxane. 
Selenium dioxide (1.54 g, 4 eqv.) was added with vigorous stirring. The reaction mixture was flushed 
with argon and then refluxed at 100 oC for 12 h. The reaction mixture was filtered through cotton plug. 
The filtrate was then concentrated under reduced pressure and the crude mixture was subjected to flash 
chromatography to obtain a yellow solid (513 mg, 88%) yield. The starting material and product were 
inseparable with chromatography. Yellow solid, mp 94.1-96.8 oC (mixture), 1H NMR (400 MHz, 
CDCl3), δ (ppm) 9.78 (s, 1H), 5.73 (s, 1H), 3.87 (s, 3H), 2.26 (s, 3H). 13C NMR (100.53 MHz, CDCl3), 
δ (ppm) 169.0, 161.4, 148.2, 118.6, 94.4, 56.8, 8.2, MS-C8H8O4 (168.04), m/z (%): Found 168 (M+)  
 
Synthesis of compound ester (9) 
                                            
 
 
Phosphonate ester (8) (140 mg, 0.62 mmol) was placed in a round bottom flask along with 10 mL toluene. 
The mixture was flushed with argon and then cooled to 0 oC, successively potassium tert-butoxide (73 
mg, 0.65 mmol) was added and the reaction mixture was stirred for 15 min at 0 oC. Aldehyde (7) (35 
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mg, 0.20 mmol) was dissolved in 5 mL tetrahydrofuran and then added drop-wise to above flask for over 
a period of 5 min. The reaction mixture then stirred at 0 oC for 1 h. The reaction was quenched with 10 
mL water, warmed to room temperature and product was extracted in ethyl acetate. Chromatography 
purification using 2:8 hexanes/ethyl acetate mixture provided the expected product (9) as white solid 
(42.9 mg, 90%) yield. mp 143.0-144.1 oC, 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.45 (d, J = 15.9 Hz, 
1H), 6.70 (d, J = 15.9 Hz, 1H), 5.59 (s, 1H), 4.22 (q, J = 7.20 Hz, 2H), 3.82 (s, 3H), 2.03 (s, 3H), 1.28 
(t, J = 7.20 Hz, 3H), 13C-NMR (100.53 MHz, CDCl3), δ (ppm) 169.6, 166.1, 162.4, 151.3, 130.77, 124.2, 
113.5, 91.3, 60.9, 56.3, 14.1, 9.3, MS-C12H14O5 (238.08), Found 238 (M
+) 
 
Synthesis of compound (2) (Herbarin B) 
 
Ester (9) (25 mg, 0.105 mmol) was placed in a round-bottom flask along with 10 mL of 3M HCl. The 
mixture was heated to 70 oC and stirred for 12 h.  The reaction mixture was cooled to 0 oC. Product was 
deposited at the bottom as white solid. This solid was washed with water (10 mL x 2), the product was 
then recrystallized with isopropyl alcohol to obtain a white solid (21.6 mg, 98 %) yield. mp 250.3-252 
oC, 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.54 (d, J = 15.4 Hz, 1H), 6.61 (d, J = 15.4 Hz, 1H), 5.79 (s, 
1H), 3.95 (s, 3H), 2.11 (s, 3H), 13C-NMR (100.53 MHz, CD3OD), δ (ppm) 172.2, 169.0, 165.2, 152.7, 
132.4, 125.4, 115.7, 92.1, 9.4, MS-C10H10O5 (210.05), Found 210 (M
+)  
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Synthesis of compound ester (11) 
 
Phosphonate ester (10) (308 mg, 1.23 mmol) was placed in a round-bottom flask along with 10 mL 
toluene. The mixture was flushed with argon and then cooled to 0 oC, successively potassium tert-
butoxide  (143 mg, 1.27 mmol) was added and the reaction mixture was stirred for 15 min at 0 oC. 
Aldehyde (7) (69 mg, 0.41 mmol) was dissolved in 5 mL tetrahydrofuran and then added drop-wise to 
above flask for over a period of 5 min. The reaction mixture then stirred at 0 oC for 1 h. The reaction 
was quenched with 10 mL water, warmed to room temperature and product was extracted in ethyl 
acetate. Chromatography purification using 2:8 hexanes/ethyl acetate mixtures provided the expected 
product (11) as yellow solid ( 87.8 mg, 81 %) yield. mp 131.5-135.1 oC, 1H-NMR (400 MHz, CDCl3) δ 
(ppm) 7.37 (dd, J = 3.67, 14.9 Hz, 1H), 7.19 (dd, J = 3.67, 14.92 Hz,1H), 6.68 (d, J = 15 Hz, 1H), 6.09 
(d, J = 15 Hz, 1H), 5.55 (s, 1H), 4.22 (q, J = 7.20 Hz, 2H), 3.82 (s, 3H), 1.99 (s, 3H), 1.30 (t, J = 7.20 
Hz, 3H), 13C-NMR (100.53 MHz, CDCl3), δ (ppm) 170.1, 166.4, 163.1, 152.7, 142.3, 132.3, 126.2, 
125.3, 110.8, 90.1, 60.6,  56.3, 14.2, 9.0, MS-C14H16O5 (264.10), Found 264 (M
+)  
 
Synthesis of compound (1) (Herbarin A) 
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Ester (11) (48 mg, 0.182 mmol) was placed in a round-bottom flask along with 10 mL of 3M HCl. The 
mixture was heated to 70 oC and stirred for 12 h.  The reaction mixture was cooled to 0 oC. Product was 
deposited at the bottom as white solid. This solid was washed with water (10 mL x 2), the product was 
then recrystallized with isopropyl alcohol to obtain a white solid (28.8 mg, 67 %) yield. mp 241.9-243.2 
oC, 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.48 (dd, J = 3.60, 15 Hz, 1H), 7.19 (dd, J = 3.60, 15 Hz,1H), 
7.01 (d, J = 15 Hz, 1H), 6.20 (d, J = 15 Hz, 1H), 5.70 (s, 1H), 3.92 (s, 3H), 2.07 (s, 3H), 13C-NMR 
(100.53 MHz, CD3OD), δ (ppm) 172.2, 168.2, 165.6, 154.3, 144.4, 133.3, 128.3, 126.1, 113.0, 90.8, 
57.0,  9.5, MS-C12H12O5 (236.08), Found 236 (M
+)  
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APPENDIX B 
ANALYTICAL METHODS 
 
MATERIALS: All the starting materials were purchased from Aldrich and used without further 
purification. Anhydrous solvents were obtained as follows: Anhydrous tetrahydrofuran and 
anhydrous dichloromethane were dried via distillation from CaH2 immediately prior to use under 
argon, and anhydrous DMF was stored at 4 Å molecular sieves before use. Other solvents used in 
synthesis with minimum purity of 99.5% were Aldrich products. CDCl3 or (CD3)2CO were used 
as a solvents (99.8%) for the NMR studies. Thin Layer Silica Gel Chromatography Plates (60 Å, 
250 µm thickness, F-254 indicator). Flash chromatography was performed using 230-400 mesh, 
60 Å pore diameter silica gel. Chromatography solvents used were reagent grade.  
 
NMR ANALYSIS: The 1H NMR spectra were obtained at 400 MHz using Agilent NMR 
spectrometer. 13C NMR spectra were recorded at 100 MHz. Chemical shifts are reported in parts 
per million and are referenced to the deuterated residual solvent peak. NMR data is reported as: δ 
value (chemical shift, J-value (Hz), integration, where s = singlet, d = doublet, t = triplet, q = 
quartet, bs = broad singlet).  
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APPENDIX B 
SUPPORTING INFORMATION CHAPTER 3 
Synthesis of TBDMS protection of inosine (13) 
 
Inosine (12) (1g, 0.037 mmol) was placed in a 100 mL RB flask along with 15 mL of DMF. 
TBDMS-Cl (0.018 mmol) and imidazole (0.026 mmol) were added to the above reaction mixture. 
The reaction mixture was stirred at room temperature for 12 hours. The crude reaction mixture 
was then transferred to a separatory funnel, and product was extracted in DCM and washed with 
water. The organic layer was then passed over sodium sulfate and concentrated to remove residual 
excess solvent. The white solid was then washed with cold ethanol to remove the traces of 
TBDMS-Cl, to provide a white solid 634 mg.  
1H NMR (400 MHz, CDCl3), δ (ppm) 8.22 (s, 1H), 8.14 (s, 1H), 6.01 (d, J = 4.9 Hz, 1H), 4.49 (t, J = 4.94 
Hz, 1H), 4.28 (t, J = 4.82 Hz, 1H), 4.11 (dd, J = 3.71, 3.03 Hz, 1H), 3.98 (dd, J = 11.2, 4.16 Hz, 1H), 3.77 
(dd, J = 11.2, 2.5 Hz, 1H), 0.94 (s, 9H), 0.91 (s, 9H), 0.74 (s, 9H), 0.13 (s, 1H), 0.12 (s, 1H), 0.08 (s, 1H), 
0.07 (s, 1H), -0.04 (s, 1H), -0.19 (s, 1H). 13C NMR (100.53 MHz, CDCl3), δ (ppm) 159.3, 148.8, 144.7, 
139.0, 124.9, 88.2, 85.4, 76.5, 71.7, 62.3, 26.0, 25.8, 25.7, 18.5, 18.0, 17.8, -4.4, -4.7, -4.7, -5.0, -5.4, -5.4  
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Synthesis of C-6 chloro-inosine (14) 
 
Protected inosine (13)  (100 mg, 0.16 mmol) was in a 50 mL RB flask along with 10 mL DCM 
and the reaction mixture was purged with argon. Later 0.5 mL DMF and triethylamine (46 uL, 
0.32 mmol) were added successively. The reaction mixture was then cooled to 0°C and thionyl 
chloride (15 uL, 0.19 mmol) was added drop-wise. The reaction was allowed to warm to RT and 
stirred for 3 h. After complete conversion, as indicated on TLC, excess solvent was evaporated 
under reduced pressure and resulting product was used for next step without further purification.    
 
Synthesis of 2-methyl azaarene C-6 conjugated product (16) 
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C-6 chloro inosine (14) (50 mg) was placed on a 25 mL RB flask and 5 mL of Dioxane was added 
under argon. DBU (200 uL) was added and the reaction mixture was heated to 80 °C for 12 h. No 
product formation was observed on TLC so the same reaction mixture was then further heated to 
110 °C for 12 h.  No product formation was observed under basic conditions. Similar reaction 
parameters were then tried using a Lewis acid catalyst Yb(OTf)3  at 110 °C, however, the reaction 
did not provide the expected product. 
 
Reaction C-6 hydroxyl inosine with 2-mesitylenesulfonyl chloride (19) 
  
Protected inosine (13) (100 mg, 0.16 mmol) was dissolved in 5 mL of DCM, followed by addition 
of DMAP (2.0 mg, 0.016 mmol) and triethylamine (45.7 uL, 0.32 mmol) into a RB flask under 
argon. 2-mesitylene sulfonyl chloride (18) (71.7 mg, 0.32 mmol) was then added to the reaction 
mixture and allowed to proceed at RT for 3 hours. After the complete conversion, the reaction 
mixture was diluted with DCM and poured into a separatory funnel along with 50 mL water. The 
product was extracted in DCM and washed with water followed by dilute NaHCO3 solution. The 
organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure 
to obtain a viscous liquid. The product was used further without any purification. 
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Reaction of C-6 mesitylenesulfonate with quinaldine (16) 
 
Product (19) was dissolved in dichloromethane (30 mL) and was added to quinaldine (31.3 mg) 
along with triethylamine (365 uL) at 0°C, and the resulting mixture was stirred for 10 min. DBU 
(30 uL) was added, and stirred for 10 h at RT. The reaction mixture was poured into 
dichloromethane, washed with water and brine, and concentrated. The crude product was purified 
using flash chromatography (1:1 ethyl acetate/hexane) to give expected conjugated product (16). 
1H NMR (400 MHz, CDCl3), δ (ppm) 8.82 (s, 1H), 8.16 (t, J = 8.04 Hz, 1H), 7.96 (d, J = 8.04 Hz, 1H), 
7.80 (d, J = 7.55 Hz, 1H), 7.70 (dt, 7.92 Hz, 1H), 7.56 (d, J = 9.16 Hz, 1H), 7.53 (t, J = 7.18 Hz, 1H), 6.93 
(d, J = 15.3 Hz, 1H), 6.01 (d, J = 5.19 Hz, 1H), 5.23 (s, 2H), 4.42 (t, J = 4.12 Hz, 1H), 4.24 (t, J = 4.19 Hz, 
1H), 4.10 (dd, J = 3.45, 3.11 Hz, 1H), 3.93 (dd, J = 11.8, 4.0 Hz, 1H), 3.76 (dd, J = 11.8, 2.11 Hz, 1H), 
0.92 (s, 9H), 0.91 (s, 9H), 0.80 (s, 9H), 0.11 (s, 1H), 0.10 (s, 1H), 0.08 (s, 1H), 0.05 (s, 1H), -0.03 (s, 1H), 
-0.20 (s, 1H). 13C NMR (100.53 MHz, CDCl3), δ (ppm) 145.1, 143.1, 141.2, 140.0, 138.1, 137.1, 132.2, 
131.7, 129.7, 129.0, 128.1, 127.6, 126.9, 119.2, 88.1, 85.6, 71.5, 26.0, 25.7, 25.6, 22.6, 22.5, 0.9, -4.4, -4.6, 
-4.7, -4.7, -4.7, -5.0, -5.4, -5.4  
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Reaction of C-6 mesitylenesulfonate with 2-methyl pyridine (21) 
 
Product (19) was dissolved in dichloromethane (30 mL) and was added to picoline (21.47 mg) 
along with triethylamine (365 uL) at 0°C, and the resulting mixture was stirred for 10 min. DBU 
(30 uL) was added, and stirred for 10 h at RT. The reaction mixture was poured into 
dichloromethane, washed with water and brine, and concentrated. The crude product was 
purified using flash chromatography (1:1 ethyl acetate/hexane) to give expected conjugated 
product (21).  
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Deprotection of coupled product (21) by TBAF (22) 
 
To a solution of product (21) (20 mg, 0.011 mmol) in THF (5 mL) was added 1 M TBAF in THF 
(0.5 mL, 0.05 mmol). The mixture was stirred at room temperature until completion of the reaction 
as shown by TLC (DCM/MeOH). The solvent was removed under reduced pressure, and the 
product was isolated by column chromatography on silica gel (DCM/MeOH, 9:1) followed by 
recrystallization with MeOH/ H2O (1:1) to afford the title nucleoside (22) as a white solid.  
1H NMR (400 MHz, (CD3)2CO), δ (ppm) 8.57 (d, J = 4.71 Hz, 1H), 8.47 (d, J = 3.33 Hz, 1H), 7.80 (dt, J 
= 7.60, 1.81 Hz, 1H), 7.55 (d, J = 7.54 Hz, 1H), 7.31 (dd, J = 7.21, 4.73 Hz, 1H), 6.07 (d, J = 6.47 Hz, 1H), 
5.74 (s, 2H), 5.07 (dd, J = 8.48, 3.58 Hz, 1H), 4.85 (dd, J = 10.71, 5.83 Hz, 1H), 6.23 (dd, J = 6.36, 3.15 
Hz, 1H), 4.46 (dd, J = 4.21, 2.14 Hz, 1H), 4.41 (dd, J = 6.76, 4.10 Hz, 1H). 13C NMR (100.53 MHz, 
(CD3)2CO), δ (ppm) 151.2, 149.6, 142.8, 136.6, 122.7, 121.4, 89.8, 189.79, 86.93, 86.91, 74.2, 71.9, 71.3, 
68.5, 62.2, 61.2 
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